Dr. MacLeman, 43, was appointed as Chief Executive Officer on 4 May 2009.  He is the current Chairman of the Ausbiotech Agricultural, Environmental and Industrial Advisory Committee and was most recently Chief Executive Officer of Hatchtech Pty. Limited where he led the company from research through to international Phase II human clinical trials.  Dr. MacLeman was responsible for opening up animal health and agricultural opportunities, climaxing in an agreement with one of the top three global chemicals companies.  Prior to this, he was Chief Operating Officer of Imugene Ltd. and Vice President at Agenix Ltd.  Dr. MacLeman has also previously founded life sciences start-ups and worked in investment banking focusing on the analysis and financing of technology companies.

Mr. Howitt, 45, was appointed as the Group’s first full-time Chief Financial Officer in June 2004 and as Company Secretary in June 2005.  During his 20-plus year career, he has served as CFO and Company Secretary for a number of companies, listed on both the ASX and foreign stock exchanges.  His wide experience covers all facets of financial management and control across a variety of industries, including resources and technology (domestic and international), having been instrumental in the successful development, patenting and commercialisation of several innovative technologies.  He has played key roles in the raising of bank debt and equity capital and the management of complex due diligence programs and has worked as a senior Taxation Consultant for Ernst & Young and in the investment banking industry.  He also serves as President of the Company’s Canadian-listed subsidiary, Gtech International Resources Limited.

Ms. Mew, 51, was appointed as the Group’s Chief Operating Officer on 31 August 2009.  Prior to joining the Group, she had extensive experience in the bio-pharmaceutical industry in operations management roles - both in Australia and overseas.  Her most recent corporate experience was 13 years with CSL Ltd., in senior executive positions across the Animal Health, Biosciences and Pharmaceutical Divisions - managing vaccines, diagnostics and other biologicals manufacture.  Just prior to joining Genetic Technologies Limited, Ms. Mew spent three years providing consulting services in both operational and strategic management areas to both local and international organizations.

Dr. Sparling, 37, was appointed as the Group’s first Vice President Legal and Corporate Development on 26 October 2009.  He is an experienced corporate development executive who has been appointed to drive M&A, expansion and strategy development.  Dr. Sparling’s expertise includes: senior executive management, intellectual property maintenance and defence, licensing, corporate governance, corporate finance and strategic planning.  His experience extends to both pharmaceutical and diagnostic applications; in both human and animal health.  Prior to joining the Group, Dr. Sparling was chief operating officer for Solbec Pharmaceuticals Ltd., a publicly listed bio-pharmaceutical company based in Perth, Western Australia.  Dr. Sparling is currently a director of Solbec Pharmaceuticals (now named Freedom Eye Ltd.).  Prior to this, he was Commercial Counsel for Agenix Limited, an ASX listed biotechnology company based in Queensland.

Mr. McPherson, 45, was appointed as the Group’s first Vice President Sales and Marketing on 20 July 2009.  He brings over 20 years experience in developing both retail and consumer businesses in Australia and the Asian region, including the development of new retail formats and multi-media campaigns for chains such as Mitre 10, Spotlight and Symbion Health.  There, his expertise in multi-site customer operations translated strategy into broad line management accountability.  Overseas assignments in Asia for Whirlpool Corporation included setting up Joint Ventures in China and India and Pan-Asian supplier negotiations.  Whilst working in Australia, he assisted in the development of manufacturer/wholesalers such as Electrolux, Whirlpool and Brivis/Carrier, where he implemented advanced measurement and process improvement techniques directly increasing profitability and shareholder value.

Mr. Stuart, 51, was appointed General Manager of Phenogen Sciences Inc., Genetic Technologies’ North American subsidiary. Phenogen Sciences has marketing rights to BREVAGen™, the proprietary Non-Familial Breast Cancer risk test as the first of a suite of novel advanced cancer management tools.

Lewis has more than 28 years of experience in general management, sales and marketing in pharmaceutical and life sciences.  Most recently Lewis served as Senior Vice President, Commercial Operations at cardiovascular drug developer CV Therapeutics, where he led the launch of their lead product and played a significant role in growing that company’s market cap from $300 million to the $1.5 billion acquisition by Gilead.  There, Lewis had responsibility for sales, marketing, medical affairs, managed care, operations and investor relations and built the company’s 325 person commercial team and related infrastructure.

Prior to CVT, Mr. Stuart held senior US and European sales and marketing positions within the health care sector, including six years as Vice President, Sales at Agouron Pharmaceuticals, Inc. (now a Pfizer company) and Bristol Myers Squibb.